Cargando…

Uniform Noting for International Application of the Tumor-Stroma Ratio as an Easy Diagnostic Tool: Protocol for a Multicenter Prospective Cohort Study

BACKGROUND: Colon cancer treatment is dependent on the stage at diagnosis. The current Tumor-Node-Metastasis (TNM) staging for the selection of patients for adjuvant chemotherapy needs additional prognostic and predictive biomarkers. Better decision making for chemotherapy will result in reducing ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smit, Marloes, van Pelt, Gabi, Roodvoets, Annet, Meershoek-Klein Kranenbarg, Elma, Putter, Hein, Tollenaar, Rob, van Krieken, J Han, Mesker, Wilma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2019
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595942/ https://www.ncbi.nlm.nih.gov/pubmed/31199317 http://dx.doi.org/10.2196/13464

Ejemplares similares

Tumour-stroma ratio outperforms tumour budding as biomarker in colon cancer: a cohort study
por: Smit, Marloes A., et al.
Publicado: (2021)

e-Learning for Instruction and to Improve Reproducibility of Scoring Tumor-Stroma Ratio in Colon Carcinoma: Performance and Reproducibility Assessment in the UNITED Study
por: Smit, Marloes A, et al.
Publicado: (2021)

Tumor stroma as contributing factor in the lymph node metastases process?
por: Mesker, Wilma E., et al.
Publicado: (2019)

Deep learning based tumor–stroma ratio scoring in colon cancer correlates with microscopic assessment
por: Smit, Marloes A., et al.
Publicado: (2023)

Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
por: Zunder, Stéphanie M., et al.
Publicado: (2018)

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer
por: Hagenaars, Sophie C., et al.
Publicado: (2021)

The intra-tumoural stroma in patients with breast cancer increases with age
por: Vangangelt, Kiki M. H., et al.
Publicado: (2019)

Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
por: Sandberg, Tessa P., et al.
Publicado: (2018)

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content
por: Sandberg, Tessa P., et al.
Publicado: (2019)

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer
por: Vangangelt, Kiki M.H., et al.
Publicado: (2020)

The Stroma Liquid Biopsy Panel Contains a Stromal-Epithelial Gene Signature Ratio That Is Associated with the Histologic Tumor-Stroma Ratio and Predicts Survival in Colon Cancer
por: Ravensbergen, Cor J., et al.
Publicado: (2021)

The role of artificial intelligence to quantify the tumour-stroma ratio for survival in colorectal cancer
por: Smit, Marloes A, et al.
Publicado: (2020)

Standardization of the tumor-stroma ratio scoring method for breast cancer research
por: Hagenaars, Sophie C., et al.
Publicado: (2022)

Combined Assessment of the Tumor–Stroma Ratio and Tumor Immune Cell Infiltrate for Immune Checkpoint Inhibitor Therapy Response Prediction in Colon Cancer
por: Ravensbergen, Cor J., et al.
Publicado: (2021)

Scoring the tumor-stroma ratio in colon cancer: procedure and recommendations
por: van Pelt, G. W., et al.
Publicado: (2018)

Prognostic value of tumor–stroma ratio combined with the immune status of tumors in invasive breast carcinoma
por: Vangangelt, K. M. H., et al.
Publicado: (2017)

Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients
por: van de Weerd, Simone, et al.
Publicado: (2022)

Presence of a High Amount of Stroma and Downregulation of SMAD4 Predict for Worse Survival for Stage I–II Colon Cancer Patients
por: Mesker, Wilma E., et al.
Publicado: (2009)

Comment on: The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer
por: Mesker, W E, et al.
Publicado: (2015)

N-Glycomic Signature of Stage II Colorectal Cancer and Its Association With the Tumor Microenvironment
por: Boyaval, Fanny, et al.
Publicado: (2021)

The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review
por: Kramer, C. J. H., et al.
Publicado: (2018)

Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer
por: Sandberg, Tessa P., et al.
Publicado: (2019)

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial
por: Dijkstra, Esmée A., et al.
Publicado: (2023)

Characteristics of tumour stroma in regional lymph node metastases in colorectal cancer patients: a theoretical framework for future diagnostic imaging with FAPI PET/CT
por: Polack, Meaghan, et al.
Publicado: (2022)

Are disseminated tumor cells in bone marrow and tumor-stroma ratio clinically applicable for patients undergoing surgical resection of primary colorectal cancer? The Leiden MRD study
por: Vogelaar, F. J., et al.
Publicado: (2016)

The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer
por: van Pelt, G.W., et al.
Publicado: (2019)

Results of a diagnostic imaging audit in a randomised clinical trial in rectal cancer highlight the importance of careful planning and quality control
por: Prata, Ilaria, et al.
Publicado: (2023)

N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression
por: Holst, Stephanie, et al.
Publicado: (2016)

Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer
por: Blok, Erik J., et al.
Publicado: (2017)

AVOID; a phase III, randomised controlled trial using indocyanine green for the prevention of anastomotic leakage in colorectal surgery
por: Meijer, Ruben P J, et al.
Publicado: (2022)

Clinical impact of different detection methods for disseminated tumor cells in bone marrow of patients undergoing surgical resection of colorectal liver metastases: a prospective follow-up study
por: Vogelaar, F Jeroen, et al.
Publicado: (2010)

Watch and wait after neoadjuvant treatment in rectal cancer: comparison of outcomes in patients with and without a complete response at first reassessment in the International Watch & Wait Database (IWWD)
por: Temmink, Sofieke J D, et al.
Publicado: (2023)

Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect - a histopathological and immunohistochemical study
por: Nagtegaal, Iris D, et al.
Publicado: (2001)

Detection of Tumor Cells in Bone Marrow, Peripheral Blood and Lymph Nodes by Automated Imaging Devices
por: Mesker, Wilma E., et al.
Publicado: (2006)

Tumour‐stroma ratio has poor prognostic value in nonpedunculated T1 colorectal cancer: A multicentre case‐cohort study
por: Dang, Hao, et al.
Publicado: (2021)

Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study
por: Hagenaars, Sophie C., et al.
Publicado: (2022)

Chemotherapy resistance and stromal targets in breast cancer treatment: a review
por: van der Spek, Y. M., et al.
Publicado: (2020)

Prognostic value of tumor markers and ctDNA in patients with resectable gastric cancer receiving perioperative treatment: results from the CRITICS trial
por: Slagter, Astrid E., et al.
Publicado: (2021)

Improved classification of breast cancer peptide and protein profiles by combining two serum workup procedures
por: Velstra, Berit, et al.
Publicado: (2012)

Ten-year distant-recurrence risk prediction in breast cancer by CanAssist Breast (CAB) in Dutch sub-cohort of the randomized TEAM trial
por: Zhang, Xi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kqsr41r4eq2t9adis3ootu315b